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Abstract
A library of pinane-based 2-amino-1,3-diols was synthesised in a stereoselective manner. Isopinocarveol prepared from
(−)-α-pinene was converted into condensed oxazolidin-2-one in two steps by carbamate formation followed by a stereoselective
aminohydroxylation process. The relative stereochemistry of the pinane-fused oxazolidin-2-one was determined by 2D NMR and
X-ray spectroscopic techniques. The regioisomeric spiro-oxazolidin-2-one was prepared in a similar way starting from the commer-
cially available (1R)-(−)-myrtenol (10). The reduction or alkaline hydrolysis of the oxazolidines, followed by reductive alkylation
resulted in primary and secondary 2-amino-1,3-diols, which underwent a regioselective ring closure with formaldehyde or
benzaldehyde delivering pinane-condensed oxazolidines. During the preparation of 2-phenyliminooxazolidine, an interesting
ring–ring tautomerism was observed in CDCl3.
Introduction
The best known 2-amino-1,3-diol derivative sphingosine (1)
plays a crucial role in intracellular signaling as second
messenger, and its derivatives called sphingolipids are also crit-
ical for cell growth, cell differentiation, cell recognition, and ap-
optosis [1-7]. Due to its involvement in a wide range of cellular
processes, significant efforts have been made in the last two
decades targeting sphingosine analogues signalling as a thera-
peutic strategy. For instance, FTY720-P (3), the phosphate of
FTY720 (2, fingolimod), proved to be a very good agonist for
the S1P1 receptor (Figure 1). Sphingosine 1-phosphate (S1P, 4),
in turn, performed critical regulator functions in many physio-
logical and pathological treatments, such as Alzheimer’s disease
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Figure 1: Biologically active 2-amino-1,3-diols.
[8,9], cancer [10-13], multiple sclerosis [14], and inflammation
[15].
Due to the lack of a readily available natural sources and the
high biological importance of sphingolipid analogues, their syn-
thesis has been the subject of numerous studies [16]. The key
step for the synthesis is the stereoselective construction of the
2-amino-1,3-diol moiety of the molecules. Generally, two main
synthetic strategies are used to prepare these analogues. One
requires the insertion of the alcohol and amino groups in the α,β
position with the correct stereochemistry [17-20]. The second
strategy involves a bond formation between two chiral centers
to produce the targeted 2-amino-1,3-diol [21,22]. For instance,
deoxoprosophylline (5) as a cyclic 2-amino-1,3-diol target mol-
ecule was prepared by Kokatla et al. in an 8 step synthesis
starting from Perlin aldehydes, via Pd(OH)2-catalyzed reduc-
tive azidoketon cyclisation [23]. Another synthetic pathway
involves a stereoselective aminohydroxylation process starting
from allylic carbamates usually carried out in the presence of
potassium osmate [24-28].
In recent years, we have extensively studied the stereoselective
synthesis, as well as catalytic and pharmacological applications
of monoterpene-based 3-amino-1,2-diols, which are the regio-
isomers of potential monoterpenic 2-amino-1,3-diols [29-33].
These trifunctionalized terpenoids may also possess diverse bio-
logical activities and could successfully applied as chiral cata-
lysts in enantioselective transformations [34]. In the present
study, our aim was to synthesize novel, cyclic potentially ana-
logues of sphingosine, incorporating a lipophilic natural pinane
skeleton, starting from commercially available monoterpene-
based allylic alcohols via a stereoselective hydroxyamination in
the presence of a potassium osmate(VI) catalyst. We also
planned to explore the regioselectivity of the ring closure of the
resulting 2-amino-1,3-diols to obtain promising 1,3-hetero-
cycles. To reach our goal, (1S)-(−)-α-pinene (6) and (1R)-(−)-
myrtenol (10), two naturally occurring monoterpenoids were
selected as precursors, as both are commercially available,
cheap starting materials.
Results and Discussion
Synthesis of regioisomeric oxazolidinones
from (1S)-(−)-α-pinene (6) and (1R)-myrtenol
(10)
The synthesis of isopinocarveol (7), the key intermediate allylic
alcohol, was performed according to a literature procedure in
good yield [35]. The first step was the stereoselective epoxida-
tion of (−)-α-pinene (6), carried out with meta-chloroperoxy-
benzoic acid (MCPBA), followed by a base-catalyzed allylic re-
arrangement mediated by aluminium isopropoxide (Al(OiPr)3).
The resulting allylic alcohol 7 was reacted with trichloroacetyl
isocyanate, followed by alkaline treatment, delivering carba-
mate 8 in good yield [27,28,36]. In the next step, the amino-
hydroxylation was accomplished by potassium osmate(VI) as
the catalyst and t-BuOCl in the presence of DIPEA affording
oxazolidine-2-one 9 [27]. The reaction was found to be highly
stereoselective, giving exclusively the diexo-fused tricyclic 9
ring system (Scheme 1).
The absolute configuration of compound 9 was determined by
2D NMR spectroscopic techniques. Clear NOE signals were ob-
served between the H-7a and Me-10 as well as the Ha-9 and
Me-10 protons. Beside NOESY experiments, the structure was
also elucidated by X-ray crystallography (Figure 2).
To synthesize the regioisomeric spiro-oxazolidinone derivative
12, (1R)-(−)-myrtenol (10) was chosen as starting material
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Scheme 1: Stereoselective synthesis of the pinane-fused oxazolidin-2-one 9.
Figure 2: NOESY experiments and X-ray structure elucidation of oxazolidin-2-one 9.
Scheme 2: Stereoselective synthesis of the pinane spiro-fused oxazolidin-2-one 12.
(Scheme 2). The synthetic method was similar to that
mentioned above for (−)-isopinocarveol. In the first step, carba-
mate 11 was prepared [37], then the aminohydroxylation was
carried out catalyzed by potassium osmate(VI), which led to the
formation of the spiro-oxazolidine-2-one 12 in a highly regio-
and stereoselective manner. Based on the NMR spectroscopic
measurements of the crude product, the spiro derivative 12 was
obtained exclusively with the relative configuration depicted in
Scheme 2. Beside 2D NMR spectroscopic studies, the absolute
configuration of compound 12 was determined by its transfor-
mation into the corresponding aminodiols 13 and 14, comparing
the products with those obtained from the regioisomer 9 (dis-
cussed in Scheme 3).
Synthesis and transformations of pinane-
based 2-amino-1,3-diols
To obtain a library of pinane-based 2-amino-1,3-diols, the
oxazolidine-2-ones 9 and 12 were applied as starting materials.
The alkaline hydrolysis of both 9 and 12 resulted in the same
primary aminodiol 13 [38]. According to the NMR spectra and
other physical and chemical properties, there was no difference
between the products of the two reactions. Since the relative
configuration of compound 9 was clarified by NMR spectrosco-
py and X-ray crystallographic results, we were able to assign
the stereochemistry of spiro-derivate 12, too. In a similar
manner, the LiAlH4 (LAH) reduction of both 9 and 12 gave the
same N-methylaminodiol 14 with modest yield (Scheme 3).
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Scheme 3: Parallel synthesis of 2-amino-1,3-diols.
Scheme 4: Synthesis of N-benzyl-2-amino-1,3-diol 16.
Subsequently, compound 13 was reacted with benzaldehyde. In
this process, the Schiff' base 15A was generated in situ. Our
efforts to reduce it with sodium borohydride failed, since we did
not observe the formation of the expected N-benzylaminodiol
either at room temperature or under reflux conditions, probably
due to the strong steric hindrance of the bicyclic system and the
hydroxymethyl group. The 1H NMR spectroscopic measure-
ments in CDCl3 clearly showed that the crude product was a
five-component tautomeric mixture containing condensed
oxazolidine 15E as the main component. Additional minor
components included the other condensed oxazolidine (15D),
spiro compounds 15B and 15C as well as the Schiff’ base 15A
existing in a ratio of 15A/15B/15C/15D/15E = 4:<1:4:12:79
(Scheme 4) [39,40]. The structures of the five components
15A–E were determined by 2D NMR spectroscopic techniques
(NOESY and HMBC). Since this finding is quite unusual in the
case of Schiff’ bases, we decided to study the ring/chain
tautomeric mixture (15A–E) in the reaction of 13 with
benzaldehyde by 1H NMR spectroscopy. When a time-depend-
ent 1H NMR spectroscopic measurement was accomplished, we
observed that the equilibrium composition was established
rapidly, without any significant change in the ratio of the
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Scheme 5: Synthesis of 2-amino-1,3-diols.
Figure 3: NOESY experiments and X-ray structure proofment of the structure of oxazolidine 17.
tautomers. The equilibrium shifting strongly to product 15E can
account of the difficulty of the reduction process and the neces-
sity to use a stronger reducing agent and more severe condi-
tions. The reduction step, therefore, was performed by applying
LAH, a stronger reducing agent, and longer reflux, resulting in
N-benzyl-2-amino-1,3-diol 16 (Scheme 4).
When compound 16 was treated with formaldehyde at room
temperature, pinane-fused oxazolidine 17 was obtained regiose-
lectively (Scheme 5), as it was indicated by clear HMBC corre-
lations between the CH2 of the oxazolidine ring and the anella-
tion carbons, in contrast to the results observed in the case of
the regioisomeric 3-amino-1,2-diols, where spiro-oxazolidines
formed exclusively [41]. The configuration of oxazolidine 17
was determined by 2D NMR spectroscopic techniques. Clear
NOE signals were observed between the H-7a and Me-10 as
well as the Ha-9 and Me-10 protons. In addition to NOESY ex-
periments, the structure was also elucidated by X-ray crystal-
lography (Figure 3).
The LAH reduction of oxazolidine 17 gave N-benzyl-N-methyl
analogue 18 which, alternatively, was prepared directly from
2-oxazolidinone 9 via N-benzylation followed by LAH reduc-
tion in 2 steps.
When compound 13 was reacted with phenylisothiocyanate,
thiourea 20 was obtained, which underwent a regioselective
ring closure resulting in 21A. The structure of 21A was deter-
mined by 1H (whereas the CH-OH gave a dublet in DMSO-d6
while the CH2-OH of 21B could be detected as triplet) and
2D NMR spectroscopic techniques (HMBC). It is important to
mention that this regioselectivity is the opposite to that ob-
served in the reaction of aminodiols 13 and 16 with aldehydes
(see Scheme 4 and Scheme 5), but it is similar to that observed
in our earlier study with pinane-based 3-amino-1,2-diols [41].
During the NMR spectroscopic study of 21A in CDCl3 for
30 days, an unknown slow ring–ring tautomerization was ob-
served, forming a 1:1 mixture of the two regioisomers 21A and
21B. Compound 21B could be isolated from the mixture by
column chromatography in pure form.
The synthesis of the heteroanalogue 2-phenyliminothiazo-
lidines 22A and 22B failed, even when the reaction was
attempted under acidic or even milder conditions (Scheme 6).
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Scheme 6: Synthesis of 2-phenyliminooxazolidines.
Figure 4: Proposed pathway for the ring–ring tautomerism.
The proposed reaction pathway for the ring–ring tautomerism of
21A and 21B is presented in Figure 4 and it explains why the
acidic environment (present generally in CDCl3 solution) is
necessary. In a similar manner, an oxazolidine–1,3-oxazine
tautomerism of pulegone-based 3-amino-1,2-diols was recently
reported [31]. When compound 21A or 21B were treated in less
protic solvents such as DMSO-d6 or CD3OD, tautomerization
was not observed.
Conclusion
A small library of pinane-based 2-amino-1,3-diols was synthe-
sized in a stereoselective manner starting from (1R)-(−)-
myrtenol and isopinocarveol prepared from α-pinene. Pinane-
condensed or spiro-oxazolidin-2-ones were formed in three
steps by a stereoselective hydroxyamination process. The rela-
tive stereochemistry of new compounds was determined by
2D NMR spectroscopic and X-ray techniques. The resulting pri-
mary and secondary 2-amino-1,3-diols underwent a regioselec-
tive ring closure with formaldehyde and benzaldehyde produc-
ing pinane-condensed oxazolidines. In the case of 2-phenylimi-
nooxazolidine, an interesting ring–ring tautomerism was ob-
served in CDCl3. The prepared trifunctional compounds may
serve as chiral catalysts in enantioselective transformations,
while the 2-phenyliminooxazolidines could be interesting in the
field of antiproliferative or antioxidants studies based on our
former studies on 2-imino-1,3-heterocycles [42,43].
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